A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A gynecologic oncology group study

Bacillus Calmette Guerin ◽

Oncology Group ◽

A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/0090-8258(90)90244-f ◽

1990 ◽

Vol 39 (3) ◽

pp. 239-243 ◽

Cited By ~ 23

Author(s):

William T. Creasman ◽

George A. Omura ◽

Mark F. Brady ◽

Edgardo Yordan ◽

Philip J. DiSaia ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Trial ◽

Gynecologic Oncology ◽

Stage Iii ◽

Bacillus Calmette Guerin ◽

Oncology Group ◽

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.057 ◽

2012 ◽

Vol 125 ◽

pp. S24-S25 ◽

Cited By ~ 3

Author(s):

L. Landrum ◽

J. Java ◽

C. Mathews ◽

G. Lanneau ◽

L. Copeland ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Epithelial Ovarian Cancer ◽

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: Results of a gynecologic oncology group study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(95)00252-9 ◽

1996 ◽

Vol 34 (1) ◽

pp. 139-147 ◽

Cited By ~ 14

Author(s):

Marcus E. Randall ◽

Rolland J. Barrett ◽

Nick M. Spirtos ◽

Eva Chalas ◽

Howard D. Homesley ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Abdominal Radiotherapy

Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.05.012 ◽

2005 ◽

Vol 99 (1) ◽

pp. 71-79 ◽

Cited By ~ 37

Author(s):

Benjamin E. Greer ◽

Brian N. Bundy ◽

Robert F. Ozols ◽

Jeffrey M. Fowler ◽

Daniel Clarke-Pearson ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Explanatory Analysis ◽

Second Look ◽

Resected Stage

Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

International Journal of Gynecology & Obstetrics ◽

10.1016/0020-7292(90)90154-d ◽

1990 ◽

Vol 32 (4) ◽

pp. 398-398

Author(s):

WT Creasman ◽

S Gall ◽

BN Bundy ◽

J Beecham ◽

R Mortel

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Second Look ◽

Minimal Residual

Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

Gynecologic Oncology ◽

10.1016/0090-8258(89)90083-8 ◽

1989 ◽

Vol 35 (3) ◽

pp. 378-382 ◽

Cited By ~ 22

Author(s):

William T. Creasman ◽

Stanley Gall ◽

Brian N. Bundy ◽

Jackson Beecham ◽

Rodrigue Mortel ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Second Look ◽

Minimal Residual

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.06.021 ◽

2009 ◽

Vol 115 (1) ◽

pp. 81-85 ◽

Cited By ~ 16

Author(s):

Thomas C. Krivak ◽

Chunqiao Tian ◽

G. Scott Rose ◽

Deborah K. Armstrong ◽

G. Larry Maxwell

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Ca 125 ◽

Oncology Group ◽

Intravenous Chemotherapy ◽

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.04.001 ◽

2013 ◽

Vol 130 (1) ◽

pp. 12-18 ◽

Cited By ~ 85

Author(s):

Lisa M. Landrum ◽

James Java ◽

Cara A. Mathews ◽

Grainger S. Lanneau ◽

Larry J. Copeland ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Epithelial Ovarian Cancer ◽

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Randomized trial of intraperitoneal chronic phosphate therapy versus observation following negative second-look laparotomy for stage III ovarian carcinoma: a gynecologic oncology group study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/s0360-3016(02)03170-x ◽

2002 ◽

Vol 54 (2) ◽

pp. 66

Author(s):

M.A Varia ◽

F.B Stehman ◽

B.N Bundy ◽

J Benda ◽

D.L Clarke-Pearson ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Randomized Trial ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Second Look

Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5584 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5584-5584

Author(s):

Chyong-Huey Lai ◽

Elizabeth Vallikad ◽

Hao Lin ◽

Lan-Yan Yang ◽

Yu-Che Ou ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

Oncology Group ◽